Single and multiple investigation activity potential luteolin against Candida albicans, Escherichia coli and Pseudomonas aeruginosa
Özet
Candida albicans is an opportunistic pathogen that can cause invasive infections, especially under conditions of immunosuppression and dysbiosis. Its presence alongside Pseudomonas aeruginosa and Escherichia coli may lead to polymicrobial biofilm-related infections. Due to rising antimicrobial resistance, alternative therapies are being explored, including luteolin, a natural flavonoid with reported in vitro antimicrobial activity. This study evaluated the in vitro antimicrobial and antibiofilm effects of luteolin against C. albicans, E. coli, and P. aeruginosa, both individually and in combination. Methods involved determining minimum inhibitory concentrations, using scanning electron microscopy, fibroblast viability tests, ELISA-based cytokine measurements, and RT-qPCR analysis of key biofilm- and quorum-sensing-related genes (luxS, lasI, and ALS1). MIC values were 0.011 mg/mL for individual strains and 0.046 mg/mL for the polymicrobial mixture. Luteolin treatment reduced microbial adherence and improved fibroblast viability compared to infected controls. Infection increased IL-1β levels and decreased IL-10 levels, effects that luteolin partially reversed. RT-qPCR showed downregulation of selected biofilm-related genes at 2×MIC. These findings demonstrate luteolin’s measurable antimicrobial and anti-biofilm effects in vitro under controlled laboratory conditions, supporting further validation in preclinical models to assess translational potential. © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2026.
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Celebi, Demet | |
| dc.contributor.author | Celebi, Ozgur | |
| dc.contributor.author | Baser, Sumeyye | |
| dc.contributor.author | Guler, Mustafa Can | |
| dc.contributor.author | Taghizadehghalehjoughi, Ali | |
| dc.contributor.author | Aydin, Elif | |
| dc.contributor.author | Genc, Sidika | |
| dc.contributor.author | Hacimuftuoglu, Ahmet | |
| dc.date.accessioned | 2026-10-18T20:25:36.873590878Z | |
| dc.date.available | 2026-10-18T20:25:36.873590878Z | |
| dc.date.issued | 2026 | |
| dc.description.abstract | Candida albicans is an opportunistic pathogen that can cause invasive infections, especially under conditions of immunosuppression and dysbiosis. Its presence alongside Pseudomonas aeruginosa and Escherichia coli may lead to polymicrobial biofilm-related infections. Due to rising antimicrobial resistance, alternative therapies are being explored, including luteolin, a natural flavonoid with reported in vitro antimicrobial activity. This study evaluated the in vitro antimicrobial and antibiofilm effects of luteolin against C. albicans, E. coli, and P. aeruginosa, both individually and in combination. Methods involved determining minimum inhibitory concentrations, using scanning electron microscopy, fibroblast viability tests, ELISA-based cytokine measurements, and RT-qPCR analysis of key biofilm- and quorum-sensing-related genes (luxS, lasI, and ALS1). MIC values were 0.011 mg/mL for individual strains and 0.046 mg/mL for the polymicrobial mixture. Luteolin treatment reduced microbial adherence and improved fibroblast viability compared to infected controls. Infection increased IL-1β levels and decreased IL-10 levels, effects that luteolin partially reversed. RT-qPCR showed downregulation of selected biofilm-related genes at 2×MIC. These findings demonstrate luteolin’s measurable antimicrobial and anti-biofilm effects in vitro under controlled laboratory conditions, supporting further validation in preclinical models to assess translational potential. © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2026. | |
| dc.description.sponsorship | This article was prepared using the budget provided by Ataturk University Scientific Research Coordination Office, Project No. TKP-2023-11777. | |
| dc.identifier.doi | 10.1007/s00203-026-04985-5 | |
| dc.identifier.eissn | 1432-072X | |
| dc.identifier.issn | 0302-8933 | |
| dc.identifier.issue | 9 | |
| dc.identifier.pmcid | 10934766 | |
| dc.identifier.pmid | 42301347 | |
| dc.identifier.scopus | 2-s2.0-105041854113 | |
| dc.identifier.startpage | 443 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/10389 | |
| dc.identifier.volume | 208 | |
| dc.identifier.wos | WOS:001795749700002 | |
| dc.language.iso | en | |
| dc.publisher | Springer Science and Business Media Deutschland GmbH | |
| dc.relation.ispartof | Archives of Microbiology | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Anti-virulence activity | |
| dc.subject | Cytokine modulation | |
| dc.subject | Cytotoxicity | |
| dc.subject | Luteolin | |
| dc.subject | Polymicrobial biofilm | |
| dc.subject | Quorum sensing inhibition | |
| dc.subject | Anti-Bacterial Agents | |
| dc.subject | Biofilms | |
| dc.subject | Candida albicans | |
| dc.subject | Cytokines | |
| dc.subject | Escherichia coli | |
| dc.subject | Fibroblasts | |
| dc.subject | Humans | |
| dc.subject | Microbial Sensitivity Tests | |
| dc.subject | Pseudomonas aeruginosa | |
| dc.subject | Quorum Sensing | |
| dc.subject | agglutinin | |
| dc.subject | agglutinin like sequence 1 | |
| dc.subject | amoxicillin | |
| dc.subject | autoinducer synthase | |
| dc.subject | cytokine | |
| dc.subject | interleukin 10 | |
| dc.subject | interleukin 1beta | |
| dc.subject | lyase | |
| dc.subject | s ribosylhomocysteine lyase | |
| dc.subject | synthetase | |
| dc.subject | unclassified drug | |
| dc.subject | antiinfective agent | |
| dc.subject | ALS1 gene | |
| dc.subject | antibiofilm activity | |
| dc.title | Single and multiple investigation activity potential luteolin against Candida albicans, Escherichia coli and Pseudomonas aeruginosa | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 0 | |
| rdl.citation.wos | 0 | |
| rdl.department | Faculty of Pharmacy, Department of Pharmaceutical Microbiology, Erzincan Binali Yıldırım University, 24002, Erzincan, Turkey. | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.source.index | PUBMED | |
| rdl.wos.index | Science Citation Index Expanded (SCI-EXPANDED) |
